IN8BIO, Inc.
NASDAQ:INAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.5), the stock would be worth $4.3 (187% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | $1.5 |
0%
|
| 3-Year Average | 1.5 | $4.3 |
+187%
|
| 5-Year Average | 1.8 | $4.95 |
+230%
|
| Industry Average | 4.6 | $12.92 |
+761%
|
| Country Average | 2.5 | $7.09 |
+373%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
I
|
IN8BIO, Inc.
NASDAQ:INAB
|
14.6m USD | 0.5 | -0.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | -107.4 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 21.4 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 7.1 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 5.9 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 2.5 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 6.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 2.3 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
IN8BIO, Inc.
Glance View
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 19 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The firm develops ex vivo-expanded and activated gamma-delta T cell candidates based upon its capabilities in gamma-delta T cell biology, genetic engineering and cell-type-specific manufacturing capabilities, DeltEx platform. Its lead product candidate, INB-200, is a genetically modified autologous gamma-delta T cell in Phase I clinical trial. Its INB-100, its off-the-shelf allogeneic DeltEx product candidate, was developed to demonstrate the safety of donor-derived expanded and activated gamma-delta T cells that do not undergo additional genetic modification. Its INB-400 is its allogeneic DeltEx DRI product candidate to treat solid tumor cancers, including newly diagnosed glioblastoma (GBM). Its INB-300 is a preclinical program focused on developing CAR-T-enabled DeltEx DRI product candidates.
